Malaysian Genomics Resource Centre Berhad, (0155) Fair Value & Analysis
Healthcare · MY · Market cap 37.7M MYR
Fair value as of: Jun 25, 2026
Analysis
Malaysian Genomics Resource Centre Berhad, (0155) currently trades at 0.2650 MYR, while our model-based Fair Value estimate is 0.0500 MYR — implying the stock looks roughly 81.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It also provides immunotherapy and cell therapy which offers mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer cell therapies designed to strengthen the body's immune response that are relevant in the treatment of cancers, autoimmune diseases, and other complex conditions. In addition, the company offers genome sequencing and bioinformatics services; personalized supplements; cellular therapy for regenerative health; and cell-free therapy for regeneration and repair. Further, it is involved in dealing in capital markets and derivative instrumen…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Malaysian Genomics Resource Centre Berhad, (0155) undervalued?
What is the fair value of 0155?
What is the quality score of 0155?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.